A study to evaluate the effectiveness of epcoritamab in patients with Waldenström's macroglobulinemia that has returned or has not responded to previous treatments.
Waldenstrom's macroglobulinemia is a rare blood cancer that often returns after treatment, requiring ongoing monitoring through specialized diagnostic tests to detect recurrence and guide the next steps in care.
Key points
check_circleWaldenstrom's macroglobulinemia cannot be cured and will eventually return after treatment, making regular monitoring essential even when you feel completely healthy
check_circleBlood tests measuring IgM protein levels are the primary way to detect recurrence before symptoms appear, allowing for early intervention planning
check_circleBone marrow biopsies confirm recurrence by showing the percentage of abnormal lymphoplasmacytic cells that have accumulated in the bone marrow
check_circleNot all patients with rising IgM levels or confirmed recurrence need immediate treatment—a watch-and-wait approach is often appropriate if symptoms are absent
check_circleGenetic testing for MYD88 and CXCR4 mutations helps predict treatment response and guides therapy selection when the disease returns
check_circleClinical trials for recurrent disease require specific diagnostic criteria including recent bone marrow biopsy, blood tests, and imaging studies to confirm eligibility
check_circleThe duration of remission after previous treatment is one of the most important factors in predicting how well you will respond to the next therapy
check_circleMany patients with recurrent Waldenstrom's macroglobulinemia can achieve years of symptom-free remission with appropriate treatment, maintaining good quality of life despite the disease's return
Introduction: Who Should Undergo Diagnostics and When
When Waldenstrom's macroglobulinemia comes back after a period of remission, it is known as recurrent or relapsed disease. Because this condition cannot be completely cured with current treatments, most people will eventually experience a return of the disease after their initial therapy ends. Understanding when to seek diagnostic testing is crucial for managing recurrent Waldenstrom's macroglobulinemia effectively.
After completing treatment, most patients enter a phase called remission, where blood tests show reduced or undetectable levels of the abnormal IgM protein (a large antibody produced by cancer cells), and symptoms either disappear or become much less noticeable. This period of feeling well can last for months, years, or even decades, as Waldenstrom's macroglobulinemia is a slow-growing cancer. The cancer cells take time to rebuild to levels that cause problems again.
Anyone who has been treated for Waldenstrom's macroglobulinemia should undergo regular diagnostic monitoring, even when feeling completely healthy. This ongoing surveillance helps doctors catch the disease's return early, before it causes severe symptoms or complications. The frequency of these check-ups typically occurs every three to six months during the remission phase, though your healthcare team will determine the best schedule for your individual situation.
You should seek diagnostic testing immediately if you notice the return of symptoms that troubled you before treatment. These warning signs include extreme tiredness that does not improve with rest, unexplained fevers, drenching night sweats that soak your clothing or bedding, unintentional weight loss, numbness or weakness in your hands or feet, easy bruising or bleeding, frequent nosebleeds, blurred vision, headaches, dizziness, confusion, or swollen lymph nodes. These symptoms may indicate that the abnormal cells have increased to concerning levels or that the IgM protein has thickened your blood again.
Regular follow-up appointments after treatment are essential because Waldenstrom's macroglobulinemia often returns without obvious symptoms at first. Blood tests can detect rising IgM levels or changes in blood cell counts long before you feel unwell. This early detection allows your healthcare team to plan the best approach, whether that means continuing to monitor the situation or starting a new treatment regimen.
Diagnostic Methods for Recurrent Disease
When Waldenstrom's macroglobulinemia is suspected to have returned, doctors use several diagnostic methods to confirm the recurrence and assess how much the disease has progressed. These tests help distinguish recurrent Waldenstrom's macroglobulinemia from other conditions that might cause similar symptoms, and they provide information about the current state of the cancer cells in your body.
Blood tests form the cornerstone of diagnosing recurrent Waldenstrom's macroglobulinemia. When you visit your doctor for evaluation, they will order comprehensive blood work to measure the level of IgM protein in your blood. An increase in this abnormal protein is one of the clearest signs that the disease has returned. The test specifically looks at how much IgM is present, because levels above 60 grams per liter can put you at risk for hyperviscosity, a dangerous condition where your blood becomes too thick to flow properly through small vessels.
Additional blood tests evaluate your overall blood health by counting different types of blood cells. A complete blood count checks for anemia (low red blood cells causing fatigue), low white blood cell counts that increase infection risk, and low platelet counts that lead to bleeding and bruising problems. These abnormalities occur because the cancer cells crowd out healthy blood-forming cells in your bone marrow. Doctors also measure substances like beta-2-microglobulin, lactate dehydrogenase, and albumin levels, which help them understand how active the disease is and predict how you might respond to treatment.
When blood tests suggest the disease has returned, your doctor will likely recommend a bone marrow biopsy. This procedure involves taking a small sample of the spongy tissue inside your bones, usually from the hip bone, where blood cells are made. The sample is examined under a microscope to see how many abnormal lymphoplasmacytic cells (cancer cells with features of both lymphocytes and plasma cells) are present. This test confirms the diagnosis of recurrent disease and helps doctors understand the extent of bone marrow involvement.
Imaging tests help doctors see if the cancer has spread beyond the bone marrow. A chest X-ray or computed tomography (CT) scan can reveal swollen lymph nodes in the chest, abdomen, or pelvis, as well as an enlarged spleen or liver. These scans create detailed pictures of the inside of your body and help determine whether the cancer cells have accumulated in organs outside the bone marrow. Some patients may also need magnetic resonance imaging (MRI) scans or positron emission tomography (PET) scans if doctors suspect the disease has affected specific areas or if they need more detailed information about organ involvement.
Special blood tests check for complications that can occur with recurrent Waldenstrom's macroglobulinemia. A serum viscosity test measures how thick your blood has become due to excess IgM protein. If the viscosity is too high, you may need an emergency procedure called plasmapheresis, where blood is removed from your body, the abnormal protein is filtered out, and the remaining blood is returned to you. Other specialized tests look for cryoglobulins (proteins that clump together in cold temperatures and can block blood flow to fingers and toes) or check if the IgM protein is damaging nerves, causing peripheral neuropathy.
A thorough physical examination is always part of the diagnostic process for recurrent disease. Your doctor will feel for enlarged lymph nodes in your neck, underarms, and groin, and will check if your liver or spleen has become larger by pressing gently on your abdomen. They will also test your reflexes and sensation to detect signs of nerve damage, examine your skin for unusual lesions, and look at the back of your eyes to check for changes in blood vessels caused by thickened blood.
Genetic testing of the cancer cells provides important information about recurrent Waldenstrom's macroglobulinemia. Most patients have mutations in genes called MYD88 (found in about 90 percent of cases) and CXCR4 (found in about 40 percent of cases). These genetic changes help the cancer cells survive and grow. Knowing which mutations are present helps doctors choose the most effective treatment, as some therapies work better for certain genetic profiles. Patients with CXCR4 mutations, for example, tend to have higher IgM levels and more symptoms related to blood thickness.
Diagnostics for Clinical Trial Qualification
Clinical trials test new treatments or combinations of existing medications for recurrent Waldenstrom's macroglobulinemia. To participate in these studies, patients must meet specific criteria confirmed through diagnostic testing. Understanding these requirements helps patients and doctors determine whether a clinical trial might be an appropriate option when the disease returns.
Before enrolling in a clinical trial for recurrent Waldenstrom's macroglobulinemia, you must have confirmed evidence that the disease has returned and requires treatment. This confirmation comes from the same diagnostic tests used to detect recurrence in general practice. Blood tests must show elevated IgM levels that are rising over time, or you must have symptoms that significantly affect your daily activities. The trial protocol will specify exactly how high the IgM level must be or which symptoms qualify you for participation.
Most clinical trials require a recent bone marrow biopsy, typically performed within a few weeks before you start the study. This test confirms that lymphoplasmacytic cells are present in your bone marrow at a certain percentage, proving that the disease is active. The bone marrow sample may also be used for genetic testing to identify MYD88 and CXCR4 mutations. Some trials specifically enroll only patients with certain genetic profiles, while others may exclude patients whose disease has particular genetic characteristics.
Blood tests for clinical trial qualification go beyond measuring IgM levels. Researchers need to know your baseline blood cell counts, including hemoglobin, white blood cells, and platelets, to ensure you are healthy enough to tolerate the experimental treatment. If your blood counts are too low, you might not qualify for certain trials, as the treatment could make them dangerously worse. Kidney and liver function tests are also mandatory, because many medications are processed by these organs, and impaired function could lead to harmful side effects or prevent the drug from working properly.
Information about your previous treatments is crucial for clinical trial eligibility. Doctors need to know which therapies you received before, how long your remission lasted after each treatment, and whether you experienced any serious side effects. Some trials are designed specifically for patients who relapsed within 12 months of their last treatment, while others may require that you have tried and failed at least two different treatment regimens. The duration of your response to previous therapy helps researchers select appropriate candidates and predict how you might respond to the experimental treatment.
Imaging studies such as CT scans may be required at baseline before starting a clinical trial. These scans document the size of any swollen lymph nodes, spleen, or liver, creating a reference point that researchers can use later to measure whether the treatment is working. Some trials use advanced imaging techniques like PET scans to get more detailed information about disease activity throughout the body. These baseline images are repeated at specific intervals during the trial to track your response to the experimental therapy.
Cardiac function tests are often mandatory for clinical trial participation, especially if the experimental treatment includes medications known to affect the heart. An electrocardiogram (ECG) records the electrical activity of your heart, while an echocardiogram uses ultrasound to create moving pictures of your heart's structure and function. These tests ensure that your heart is strong enough to handle the treatment and provide baseline measurements that can be compared to later tests if heart problems develop during the trial.
Documentation of disease-related complications is important for some clinical trials. If you have peripheral neuropathy (nerve damage causing numbness or weakness), your neurological function will be carefully tested and graded. Trials testing medications that can worsen neuropathy may exclude patients who already have severe nerve damage. Similarly, if you have a history of hyperviscosity or other complications, detailed records of these events and how they were managed will be part of your qualification assessment.
Finally, clinical trials require informed consent, which is not a diagnostic test but is an essential part of the qualification process. You will receive detailed information about the study, including what tests will be performed, how often they will occur, what side effects to expect, and what your rights are as a participant. Understanding and agreeing to these terms is necessary before any trial-related diagnostics or treatments can begin.
Prognosis and Survival Rate
Prognosis
The outlook for patients with recurrent Waldenstrom's macroglobulinemia depends on several factors, including how long the remission lasted after the previous treatment, the patient's overall health and age, specific blood test results, and the genetic characteristics of the cancer cells. Patients who experienced a long remission period (typically more than 12 months) after their first treatment generally have a better prognosis when the disease returns, as they are more likely to respond well to subsequent therapies. The duration of response to previous treatment is one of the most important factors doctors consider when predicting outcomes and selecting the next treatment approach.
Several prognostic scoring systems help doctors estimate survival for patients with active, symptomatic Waldenstrom's macroglobulinemia. The modified staging system uses age, serum beta-2-microglobulin levels, lactate dehydrogenase, and albumin levels to classify patients into low-risk, low-intermediate, intermediate, and high-risk groups. These scores provide guidance about expected survival times and help both patients and doctors make informed decisions about treatment intensity and goals. Patients with certain genetic mutations, particularly those lacking the MYD88 mutation (about 10 percent of cases), tend to have inferior survival outcomes and a higher risk that their disease will transform into a more aggressive type of lymphoma.
While Waldenstrom's macroglobulinemia is currently incurable and will eventually return despite treatment, many patients can achieve years of symptom-free remission after treatment for recurrent disease. The availability of several effective treatment options means that most patients can be treated multiple times as the disease returns over the years. Each subsequent treatment may produce a response, though the duration of remission may become shorter with each relapse. Despite these challenges, many people with recurrent Waldenstrom's macroglobulinemia are able to maintain good quality of life and continue their normal activities for extended periods.
Survival rate
Specific survival statistics for recurrent Waldenstrom's macroglobulinemia are not clearly documented in the available sources. However, it is known that patients with asymptomatic or smoldering Waldenstrom's macroglobulinemia (those with elevated IgM and bone marrow involvement but no symptoms) have an overall survival similar to age-, sex-, and race-matched individuals from the general population. This suggests that when the disease is well-controlled and not causing symptoms, life expectancy can approach normal. Approximately 80 percent of patients with asymptomatic disease will require treatment within 10 years of diagnosis, indicating the slowly progressive nature of this condition.
The rarity of Waldenstrom's macroglobulinemia, with only about 1,000 to 1,500 new cases diagnosed each year in the United States, makes it challenging to gather large-scale survival data, particularly for recurrent disease. However, advances in treatment options over recent years, including the introduction of targeted therapies like BTK inhibitors and improved combinations of chemotherapy and immunotherapy, have likely improved outcomes for patients with recurrent disease. The slow-growing nature of this cancer means that even when it returns, periods of remission lasting months, years, or even decades are possible, allowing many patients to live long lives despite their diagnosis.
lightbulb Did you know?
01Waldenstrom's macroglobulinemia produces IgM, the largest antibody in the human body, which is why it causes blood to become thick and syrupy when levels get too high.
02About 90 percent of patients with Waldenstrom's macroglobulinemia have a mutation in the MYD88 gene, making genetic testing particularly useful for confirming the diagnosis and distinguishing it from other blood cancers.
03Some patients with recurrent Waldenstrom's macroglobulinemia develop cryoglobulins—proteins that turn into gel-like clumps when exposed to cold, causing fingers and toes to turn white or blue in cold weather.
Questions people often ask
info This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Belgium
